REG - Physiomics PLC - Strategy Update

PhysiomicsAnnouncement

08/05/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260508:nRSH5037Da&default-theme=true

RNS Number : 5037D  Physiomics PLC  08 May 2026

 

Physiomics plc

 

("Physiomics" or the "Company")

 

Strategy Update

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce that the newly
appointed Board has commenced an extensive review of the business with a clear
focus on operational optimisation, commercial execution, and shareholder value
creation.

 

The Board believes the Company possesses a number of underappreciated
strengths, including an established scientific platform, respected industry
relationships, and what appears to be a robust and dependable commercial
pipeline with significant scope for growth.

 

As part of the review process, immediate emphasis is being placed on
disciplined capital allocation and strict cost control measures throughout the
business. In alignment with shareholders, all of the new Directors have agreed
to receive a portion of their remuneration in ordinary shares in the Company.
Such ordinary shares are expected to be issued once annually by reference to
the prevailing mid market share price on the latest practicable date prior to
issue. Taking account of the combined cash and share proportions of the new
Director's remuneration, the aggregate cash cost of the Company's Board
remuneration arrangements and finance function is is expected to remain
broadly unchanged.

 

The Board, since their appointment,  has been encouraged by the positive
reception received from employees and consultants across the business. In
particular, CEO Peter Sargent has been accommodating, professional and
supportive throughout the transition process, and discussions are ongoing
regarding the potential extension of his contract with the Company.
Furthermore, Ian Bagnall is moving to an executive role as Finance Director
and Company Secretary with immediate effect.

 

The Board has already identified a number of additional commercial
opportunities and strategic targets which it believes can be pursued within
existing budgetary frameworks and which may materially enhance the Company's
medium-term prospects. The Board are also considering further Board
appointments, as appropriate, to enhance both operational capability and the
Company's independent governance.

 

The Board has also been made aware of recent unfounded market speculation
concerning alleged substantial exit packages payable to former personnel. The
Board confirms unequivocally that the Company has made no payments outside of
contractual entitlements to former directors or employees.

 

The Board's initial assessment of Physiomics' balance sheet is that there is a
sufficient cash runway into 2027. Following its initial assessment, the Board
believes there is a substantial opportunity to enhance operations, optimise
resources, and improve commercial delivery while maintaining the Company's
scientific credibility and client service standards.

 

The Company intends to maintain regular engagement with shareholders and
expects to provide further updates in due course regarding operational
progress, commercial developments, and additional team changes designed to
strengthen and optimise the business.

 

The Board is highly enthused by the opportunity ahead and believes Physiomics
is well positioned to enter a new phase focused on commercial growth,
operational discipline, and long-term value creation for shareholders.

 

Executive Director Mike Whitlow commented:

"We have always believed that Physiomics possesses significant potential and,
following our initial review, we are increasingly encouraged by both the
quality of the Company's scientific capabilities and the strength of its
commercial pipeline.

 

"The Board sees a clear opportunity to introduce stronger commercial focus,
tighter operational discipline and a more dynamic growth strategy, while
maintaining the high scientific standards for which Physiomics is recognised.

 

"We have been particularly encouraged by the support and professionalism shown
by the wider team during the transition period and believe the foundations are
in place to build a leaner, more commercially effective business capable of
delivering meaningful long-term shareholder value.

 

"The Board is highly motivated by the opportunity ahead and looks forward to
updating the market regularly as progress is made."

 

ENDS

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 Physiomics plc                    Email:  info@physiomics.co.uk

 Mike Whitlow

 Strand Hanson Ltd (NOMAD)         Tel:  +44 (0)20 7409 3494

 James Dance & James Bellman

 Hybridan LLP (Broker)             Tel:  +44 (0) 203 764 2341

 Claire Louise Noyce

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting- edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 140 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDEAPSXEEKKEFA



            Copyright 2019 Regulatory News Service, all rights reserved